Lyell Immunopharma, Inc. (LYEL)
12.26
-0.62
(-4.81%)
USD |
NASDAQ |
Sep 10, 15:23
Lyell Immunopharma Total Assets (Quarterly) : 311.15M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 311.15M |
| March 31, 2026 | 350.63M |
| December 31, 2025 | 340.05M |
| September 30, 2025 | 407.96M |
| June 30, 2025 | 385.45M |
| March 31, 2025 | 429.80M |
| December 31, 2024 | 490.86M |
| September 30, 2024 | 619.22M |
| June 30, 2024 | 654.14M |
| March 31, 2024 | 694.22M |
| December 31, 2023 | 750.03M |
| September 30, 2023 | 794.99M |
| Date | Value |
|---|---|
| June 30, 2023 | 835.35M |
| March 31, 2023 | 880.45M |
| December 31, 2022 | 937.56M |
| September 30, 2022 | 977.27M |
| June 30, 2022 | 1.022B |
| March 31, 2022 | 1.072B |
| December 31, 2021 | 1.127B |
| September 30, 2021 | 1.198B |
| June 30, 2021 | 1.230B |
| March 31, 2021 | 877.19M |
| December 31, 2020 | 908.28M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 77.34M |
| Shareholders Equity (Quarterly) | 233.82M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 5.356 |
| Net Debt Paydown Yield | 0.64% |